A biomarker study using tumor-infiltrating lymphocytes in patienst with biliary tract cancer

A biomarker study using tumor-infiltrating lymphocytes in patienst with biliary tract cancer - A biomarker study in biliary tract cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052526

Enrollment

Registered

2023-10-18

Start date

2023-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary tract cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who were diagnosed with biliary tract cancer and treated at Okayama University Hospital since January 2014 2. There are sufficient residual specimens collected by biopsy or other means 3. Patients who have not refused to participate in the study

Exclusion criteria

Exclusion criteria: 1. The sample volume does not remain 2. Under 20 years of age at the time of consent

Design outcomes

Primary

Measure	Time frame
Expression of CD4, CD8, FoxP3, CD25, CD45RA, CTLA-4, PD-1, ICOS, BTLA, Tim-3, LAG3, TIGIT, CD39, CD103, CD106, CCR7, CXCR5 and others in TILs evaluated by flow cytometry and/or immunostaining	—

Countries

Japan

Contacts

Public ContactYosuke Togashi

Okayama University Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences

ytogashi@okayama-u.ac.jp086-235-7390

Outcome results